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Several recent publications detailing the clinical application of next-generation sequencing 
technologies mark a milestone in the journey from base pairs to the bedside.1,2 A technology 
assessment by a major insurer lends credence to the idea that the clinical use of sequencing 
technologies is no longer viewed as a research endeavor.3 The expansion of the clinical 
application of new sequencing technologies raises a wide range of complex issues in the 
health-care system.4 Recently, Manolio and Murray5 described the outcomes of a workshop 
convened by the National Human Genome Research Institute to discuss the growing 
opportunities for educating nongeneticist physicians and other health-care providers in 
genomics. As a result of the workshop, an Inter-Society Coordinating Committee on 
Practitioner Education in Genomics was formed to facilitate interactions among professional 
societies intended to increase the expertise of practitioners in applying genomics in clinical 
care. This represents a renewed US national attempt to increase genomics competency 
among a key group of critical decision makers. In this commentary, we explore some of the 
key contextual issues that are likely to mediate genomics educational demand and ultimately 
determine the success of genomics educational programs for nongeneticist health 
professionals, especially physicians.
Physicians comprise a highly heterogeneous population. In the United States alone, there are 
24 medical specialties recognized by the American Board of Medical Specialties and 
hundreds of professional societies and organizations that play a role in the educational 
pipeline of physicians from undergraduate education through retirement. Widespread 
adoption of even simple interventions with the best evidence of health benefits—such as 
ensuring that aspirin and β-blockers are routinely employed in secondary prevention of 
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coronary heart disease—is surprisingly difficult to attain. Genomic science and the clinical 
technologies that have arisen from its application are dauntingly complex, leading a former 
director of the National Heart Lung and Blood Institute of the National Institutes of Health 
to quip regarding the translation of genomic discoveries to patient care, “If we didn’t do it 
with aspirin, how can we expect to do it with DNA?”6 Genomics has the additional burden 
of attempting to rise to the surface in a tumult of healthcare system changes.
Recognition of the need to develop a health workforce competent in genetics is not new. In 
the 1970s, papers were published exploring the issue, and the topic has been cyclically 
revisited over the intervening decades, most notably around the inception and completion of 
the Human Genome Project. Interventions in education have taken a variety of forms, from 
calls to reform medical school curricula to professional society–sponsored continuing 
medical education efforts to US federal government funding of a health professional 
organization with the sole mission of furthering the genetic literacy of all health 
professionals. The majority of these efforts have had origins in the genetics and genomics 
community. Very likely, a dispassionate grading of the results of nearly 4 decades of efforts 
to improve the genetics literacy of nongeneticist physicians and other health professionals 
would yield low marks. Limited examples of genomics educational success exist, but 
numerous publications document that the majority of physicians remain interested in 
genomics but lacking confidence and facility with the topic.
We feel that the fundamentals of the equation of cost versus benefit of attaining genomics 
competency for many physicians are shifting in favor of genomics education. This is most 
evident in the area of oncology, where the availability of new targeted therapies paired with 
knowledge of the genomic drivers of an individual patient’s tumor are improving outcomes 
for a wide variety of common cancers. This has translated to the extensive genomic 
education content offered at the 2014 meeting of the American Society of Clinical 
Oncology. The increasing alignment of incentives for provision of proven preventive 
services favors development of genomic approaches to risk stratification, as evidenced by 
the inclusion of genomics as a topic in the US Healthy People 2020 objectives. The Office 
of Public Health Genomics has introduced a three-tier classification system and continually 
updated listing of genomics applications. Applications falling into tier 1 have evidence-
based guidelines or substantial evidence supporting their use; tier 2 applications have 
sufficient evidence supporting clinical utility to consider use; tier 3 includes technologies for 
which there is little, if any, evidence supporting benefit or existing guidelines 
recommending against use. Tier 1 is, at this time, dominated by cancer-related genomic 
applications.7 It seems quite likely that consumer information demand for health-related 
technologies will drive increased information seeking on the part of physicians. Physicians 
and other health professionals already have much catching up to do to improve their 
understanding of genomics.
Available studies suggest that development and maintenance of freely available, high-
quality genomics reference and educational materials is likely insufficient to ensure a 
meaningful increase in genomics competency among nongeneticist health providers.8,9 
Meaningful increases in genomics competency will require both cultural and infrastructure 
changes that nurture and sustain a demand for knowledge regarding genomic advances 
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capable of improving patient-oriented outcomes. The success of any major genomics 
educational effort for health professionals will hinge on the ability to effectively negotiate 
three realities that confront any new health-care technology attempting to gain wide 
adoption in the United States: lack of evidence demonstrating value, incompatibility across 
health information technology/electronic health record systems, and the ever-growing time 
burden facing health professionals in the clinic (Figure 1).
First, current health-care reform efforts have improved outcomes at a reasonable cost (value) 
as a core principle. Health-care professionals are increasingly expected and incentivized to 
choose high-value interventions; those with low or unclear value are unlikely to compete 
well for clinical use, an obvious driver for educational demand. Translational research in 
genomics remains largely in the realm of early preclinical studies, and a lack of clinical 
studies that conclusively demonstrate value precludes inclusion of promising genomic 
technologies in quality metric development and incentive programs. There is a growing 
backlog of potentially beneficial genomic applications with little available data regarding 
real-world effectiveness or comparative effectiveness (tiers 2 and 3 in the Centers for 
Disease Control and Prevention’s classification scheme). Alignment of payment incentives 
to favor applications with demonstrated clinical utility would increase the probability that 
applications come to market, especially if comparative effectiveness suggests a competitive 
advantage over older, lower-value technologies. Establishment of the Patient-Centered 
Outcomes Research Institute may also help to address this backlog.
Second, electronic health records remain largely ineffectual for the management and 
interpretation of genomic information, including family health history data. Standards for 
some types of genomic data have been developed and adopted by major standards 
development organizations such as Health Level 7. However, commercial platforms have 
been slow to incorporate the standards or to facilitate the flow of structured information 
across systems necessary for automated genomic data interpretation and clinical decision 
support. Absent access to effective electronic support for the storage, exchange, 
interpretation, and use of genomic data, interest in educational efforts will be severely 
limited by the impracticality of using electronic systems outside of electronic health records 
to manage genomic data. The Meaningful Use process of the US Centers for Medicare and 
Medicaid Services is intended to help drive innovation in electronic health records and 
adoption of improved electronic functionalities, but to date little emphasis has been placed 
on developing the facility to handle genomics data.
Third is the need for adequate reimbursement for the time required to incorporate genomic 
services into patient care. Clinicians and health-care teams cannot deliver an infinite number 
of time-intensive services to patients without adequate reimbursement. Conceivably, 
comparative effectiveness research results might suggest replacement of some current 
practices with newer genomic technologies. However, genomics poses unique knowledge 
and communication issues for care providers and their patients; even with a high degree of 
genomics literacy and some degree of improved automation, genomic information will add 
to the time pressures a care team faces. As delivery structures for care such as the patient-
centered medical home and payment models based around accountable care organizations 
are developed, this real cost in time to the care team must be accounted for. Improved use of 
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information technology systems for patient and provider education might reduce some of the 
time burden in the office setting, but such sophisticated infrastructure is expensive. The 
catch-22 of this situation is that in many environments, key decision makers developing new 
models of care likely lack sufficient genomics education to plan for the potential advances 
genomics might bring to health care over the next 2 decades. Absent reimbursement for the 
time required to effectively communicate with patients regarding genomic interventions, 
physicians will likely choose to deliver (and learn about) less time-consuming interventions 
with demonstrated value.
Advancements in genomic science, coupled with changes in the health-care landscape, have 
opened potential opportunities for improved patient care and disease prevention that can 
only be fully capitalized on by an educated health professional, and in particular, physician, 
workforce. Developing such a workforce will require substantial, focused, and sustained 
resource commitment from both the public and the private sectors.10 Perseverance and 
cooperation across the entire health-care and biomedical research ecosystem are needed to 
ensure that educational efforts succeed and that the full measure of health benefits from 
genomic science are achieved.
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Figure 1. Adoption of genomic technology in clinical care requires education of health-care 
professionals
Education efforts (yellow arrow) face several contextual challenges that reduce potential 
health professional interest. First is the need to ensure that new technologies have adequate 
evidence supporting their value in improving health outcomes (green rectangle). Second, 
genomic technology must produce information that is compatible with existing electronic 
health record systems (purple rectangle). Third, health teams will need to be reimbursed 
adequately for the time required to integrate genomic information into patient care (orange 
rectangle). Increased clinical use of genomic technology is likely to have a positive effect on 
educational demand (blue arrow) and educational efforts as the number of providers exposed 
to genomics in clinical care increases.
Feero et al. Page 5
Genet Med. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
